LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and
refractory diseases that are generally treated with chemotherapy. Despite current treatment
modalities, only a subset of patients will be cured by the treatment. In this study, four
chemotherapeutic agents (L-asparaginase, Methotrexate, Doxil, and Prednisone) will be
administered in a combination regimen for patients with relapsed or refractory Peripheral
and/or advanced cutaneous T cell lymphoma. Each one of these individual drugs have been
shown to have activity to lymphomas. The objective of the study is to determine if the
combination of these chemotherapy agents results in higher response and cure rates in this
patient population. This will be a single institutional study which will included 32
patients in the Peripheral T cell lymphoma group and 32 patients in the Cutaneous T cell
lymphoma group.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of specific chemotherapy intervention
Roger Strair, MD
Principal Investigator
University of Medicine and Dentistry New Jersey
United States: Institutional Review Board
5192
NCT00161239
February 2005
October 2007
Name | Location |
---|---|
Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |